Skip to content

The efficacy and safety of Fractional Erbium:YAG assisting percutaneous absorption of triamcinolone acetonide in different dosage forms : A pilot Study

The efficacy and safety of Fractional Erbium:YAG assisting percutaneous absorption of triamcinolone acetonide in different dosage forms : A pilot Study

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230417002
Enrollment
6
Registered
2023-04-17
Start date
2023-05-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy human volunteers Drug absorption Fractional Erbium yag Steroid

Interventions

The researcher will randomly select the side of the arm to be applied with triamcinolone acetonide solution and to be applied with triamcinolone acetonide cream. On the triamcinolone acetonide solutio
Sham Comparator Device,Active Comparator Drug,Experimental Drug,Sham Comparator Device,Active Comparator Drug,Experimental Drug
Laser alone (on TA solution arm),Topical drugs alone (on TA solution arm),Laser with topical drugs combination (on TA solution arm),Laser alone (on TA cream arm),Topical drugs alone (on TA cream arm),

Sponsors

Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy Thai descendant 2. Have healthy skin, i.e., the skin on the forearm is free of inflammation, infection, and dyspigmentation. 3. Patients who voluntarily agree to participate in the study

Exclusion criteria

Exclusion criteria: 1. Being pregnant, breastfeeding, or after giving birth for no more than 3 months 2. Have open wounds, scars, infections or tattoos on the forearm 3. Perform any skin treatment (e.g., tanning, laser) on the forearm within 4 weeks prior to the start of the study. 4. Have a history of allergy to steroids 5. Have photosensitive rash or sensitivity to light 6. Have a history of using substances that affect wound healing, such as using steroids or smoking regularly

Design outcomes

Primary

MeasureTime frame
Amount of TA cream/solution in the stripped stratum corneum Immediate after treatment Measure using Ultra-High-Performance Liquid Chromatography

Secondary

MeasureTime frame
Adverse events Immediate, 2 weeks after procedure Clinical evaluation

Countries

Thailand

Contacts

Public ContactThrit Hutachoke

Faculty of Medicine Siriraj Hospital, Mahidol University

maxover2@gmail.com0818032865

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026